We read with interest the article ''Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers'' [1] published recently in your journal.
The authors refer for their review to a particular taxonomy described in a previous publication of theirs [2] , which should imply four categories: (i) coverage with evidence development (CED); (ii) performance-linked reimbursement (PLR), (iii) conditional treatment continuation (CTC), and (iv) financial/utilization arrangements (FU). Because we found the distinction between the first three categories somewhat unclear, we looked at their earlier publication and found three categories (PLR, CED, CTC), not four. This article also reported that a good example of CTC was Alzheimer medications in Italy, a multi-product scheme launched very early in 2001, which is not listed as a management entry agreement by AIFA, the Italian Medicines Agency. Then we analyzed the guidelines prepared by the International Society For Pharmacoeconomics and Outcomes Research [3] , coauthored by one of the authors, and CTC was classified under PLR, together with ''outcomes and money back guarantees'' as further sub-classification.
Because the taxonomy used in the article does not fully coincide with that in the referenced documents, we would like the authors to provide further explanation. We would be interested in understanding how the authors classified the arrangements in the UK (29) and Italy (36), which are the two leading countries in this field according to the article.
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